−0.22 EUR
−6.34 M EUR
8.46 M EUR
12.41 M
About Hyloris Pharmaceuticals SA
Sector
Industry
Website
Headquarters
Liege
Founded
2017
ISIN
BE0974363955
FIGI
BBG00V7M6KN9
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HYL is 5.30 EUR — it has decreased by −3.64% in the past 24 hours. Watch Hyloris Pharmaceuticals SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Hyloris Pharmaceuticals SA stocks are traded under the ticker HYL.
HYL stock has fallen by −10.47% compared to the previous week, the month change is a −14.24% fall, over the last year Hyloris Pharmaceuticals SA has showed a 9.28% increase.
We've gathered analysts' opinions on Hyloris Pharmaceuticals SA future price: according to them, HYL price has a max estimate of 20.00 EUR and a min estimate of 6.00 EUR. Watch HYL chart and read a more detailed Hyloris Pharmaceuticals SA stock forecast: see what analysts think of Hyloris Pharmaceuticals SA and suggest that you do with its stocks.
HYL stock is 4.56% volatile and has beta coefficient of 1.22. Track Hyloris Pharmaceuticals SA stock price on the chart and check out the list of the most volatile stocks — is Hyloris Pharmaceuticals SA there?
Today Hyloris Pharmaceuticals SA has the market capitalization of 148.40 M, it has decreased by −3.44% over the last week.
Yes, you can track Hyloris Pharmaceuticals SA financials in yearly and quarterly reports right on TradingView.
HYL net income for the last half-year is −3.56 M EUR, while the previous report showed −2.86 M EUR of net income which accounts for −24.43% change. Track more Hyloris Pharmaceuticals SA financial stats to get the full picture.
No, HYL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2025, the company has 49 employees. See our rating of the largest employees — is Hyloris Pharmaceuticals SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hyloris Pharmaceuticals SA EBITDA is −6.88 M EUR, and current EBITDA margin is −82.92%. See more stats in Hyloris Pharmaceuticals SA financial statements.
Like other stocks, HYL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hyloris Pharmaceuticals SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hyloris Pharmaceuticals SA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hyloris Pharmaceuticals SA stock shows the sell signal. See more of Hyloris Pharmaceuticals SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.